Indian Journal of Surgical Oncology

, Volume 9, Issue 4, pp 530–537 | Cite as

Safety and Efficacy of Low-Dose Single-Agent Capecitabine in Inoperable Gallbladder Cancer with Jaundice Post-Single-System Single-Catheter External Biliary Drainage: a Pilot Study from a Highly Endemic Area

  • Ravi Gupta
  • Akshay Anand
  • Manoj Kumar
  • MLB Bhatt
  • Sudhir Singh
  • Abhinav Arun SonkarEmail author
Original Article


Gallbladder cancer (CaGB) in the subcontinent belongs to low socioeconomic status, and at the time of diagnosis, a large number is unresectable or inoperable so the palliative treatment remains the only option. In the present study, attempt was made to see the effect and safety profile of single-agent oral capecitabine in inoperable CaGB in presence of low levels of jaundice post-single-catheter transhepatic external biliary drainage. In N = 35 of inoperable jaundiced CaGB, post-biliary drainage capecitabine in low dose was started when their total bilirubin levels fell to 10 mg% or below. Post-external drainage decreased bilirubin level to < 10 mg/dl within 1–4 weeks, mean 2.37 ± 0.80 weeks. Survival was 1–6 months, mean 3.26 ± 1.46 months. Catheter patency time was 1.92 ± 0.64 months (range 0–3 months). Young age, male sex, level of jaundice at presentation, and duration of decrease in jaundice after drainage were significantly associated with progressive disease course. Poor survival was significantly associated with progressive disease course, young age, and level of jaundice at admission. To the best of our knowledge, this is the first study to establish that single-agent capecitabine can be safely given in CaGB in presence of jaundice.


Low-dose capecitabine Single-system single catheter External biliary drainage Inoperable gallbladder cancer Jaundice 


Compliance with Ethical Standards

Conflicts of Interest

The authors declare that they have no conflict of interest.


  1. 1.
    Lazcano-Ponce EC, Miquel JF, Muñoz N, Herrero R, Ferrecio C, Wistuba II et al (2001) Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 51(6):349–364CrossRefGoogle Scholar
  2. 2.
    Murthy NS, Rajaram D, Gautam MS, Shivraj NS, Pruthvish S, George PS et al (2011) Trends in incidence of gallbladder cancer – Indian scenario. Gastrointestinal Cancer: Targets and Therapy 1:1–9Google Scholar
  3. 3.
    Bartlett DL, Fong Y, Fortner JG, Brennan MF, Blumgart LH (1996) Long-term results after resection for gallbladder cancer Implications for staging and management. Ann Surg 224(5):639–646CrossRefGoogle Scholar
  4. 4.
    Henson DE, Albores-Saavedra J, Corle D (1992) Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates. Cancer 70(6):1493–1497CrossRefGoogle Scholar
  5. 5.
    Ong SL, Garcea G, Thomasset SC, Neal CP, Lloyd DM, Berry DP et al (2008) Ten-year experience in the management of gallbladder cancer from a single hepatobiliary and pancreatic Centre with review of the literature. HPB (Oxford) 10(6):446–458CrossRefGoogle Scholar
  6. 6.
    Oertli D, Herzog U, Tondelli P (1993) Primary carcinoma of the gallbladder: operative experience during a 16 year period. Eur J Surg 159(8):415–420PubMedGoogle Scholar
  7. 7.
    Wade TP, Prasad CN, Virgo KS, Johnson FE (1997) Experience with distal bile duct cancers in U.S. veterans affairs hospitals: 1987-1991. J Surg Oncol 64(3):242–245CrossRefGoogle Scholar
  8. 8.
    de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM (1999) Biliary tract cancers. N Engl J Med 341(18):1368–1378CrossRefGoogle Scholar
  9. 9.
    Hawkins WG, DeMatteo RP, Jarnagin WR, Ben-Porat L, Blumgart LH, Fong Y (2004) Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Ann Surg Oncol 11(3):310–315CrossRefGoogle Scholar
  10. 10.
    Kapoor VK, Pradeep R, Haribhakti SP, Singh V, Sikora SS, Saxena R et al (1996) Intrahepatic segment III cholangiojejunostomy in advanced carcinoma of the gallbladder. Br J Surg 83(12):1709–1711CrossRefGoogle Scholar
  11. 11.
    Bismuth H, Castaing D, Traynor O (1988) Resection or palliation: priority of surgery in the treatment of hilar cancer. World J Surg 12(1):39–47CrossRefGoogle Scholar
  12. 12.
    Huibregtse K, Tytgat GN (1982) Palliative treatment of obstructive jaundice by transpapillary introduction of large bore bile duct endoprosthesis. Gut 23(5):371–375CrossRefGoogle Scholar
  13. 13.
    Cotton PB (1984) Endoscopic methods for relief of malignant obstructive jaundice. World J Surg 8:854–861CrossRefGoogle Scholar
  14. 14.
    Dowsett JF, Vaira D, Hatfield AR, Cairns SR, Polydorou A, Frost R et al (1989) Endoscopic biliary therapy using the combined percutaneous and endoscopic technique. Gastroenterology 96(4):1180–1186CrossRefGoogle Scholar
  15. 15.
    Becker CD, Glättli A, Maibach R, Baer HU (1993) Percutaneous palliation of malignant obstructive jaundice with the Wallstent endoprosthesis: follow-up and reintervention in patients with hilar and non-hilar obstruction. J Vasc Interv Radiol 4(5):597–604CrossRefGoogle Scholar
  16. 16.
    Stoker J, Laméris JS, van Blankenstein M (1993) Percutaneous metallic self-expandable endoprostheses in malignant hilar biliary obstruction. Gastrointest Endosc 39(1):43–49CrossRefGoogle Scholar
  17. 17.
    Polydorou AA, Cairns SR, Dowsett JF, Hatfield AR, Salmon PR, Cotton PB et al (1991) Palliation of proximal malignant biliary obstruction by endoscopic endoprosthesis insertion. Gut 32(6):685–689CrossRefGoogle Scholar
  18. 18.
    De Palma GD, Galloro G, Siciliano S, Iovino P, Catanzano C (2001) Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. Gastrointest Endosc 53(6):547–553CrossRefGoogle Scholar
  19. 19.
    Sherman S (2001) Endoscopic drainage of malignant hilar obstruction: is one biliary stent enough or should we place two? Gastrointest Endosc 53:681–684CrossRefGoogle Scholar
  20. 20.
    Chang WH, Kortan P, Haber GB (1998) Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. Gastrointest Endosc 47(5):354–362CrossRefGoogle Scholar
  21. 21.
    American Society for Gastrointestinal Endoscopy (ASGE) meeting 1999 Orlando, Florida, USA. May 16-19. Abstracts. Mehta S et al. endoscopic single versus double (bilateral) wallstents for palliation of malignant bismuth type III/IV hilar strictures: comparison of clinical outcomes and costs (AB234). Gastrointest Endosc. 1999 Apr;49(4 Pt 2):AB49–256Google Scholar
  22. 22.
    De Palma GD, Pezzullo A, Rega M, Persico M, Patrone F, Mastantuono L et al (2003) Unilateral placement of metallic stents for malignant hilar obstruction: a prospective study. Gastrointest Endosc 58(1):50–53CrossRefGoogle Scholar
  23. 23.
    Müller BG, De Aretxabala X, González Domingo M (2014) A review of recent data in the treatment of gallbladder cancer: what we know, what we do, and what should be done. Am Soc Clin Oncol Educ Book 34:e165–e170CrossRefGoogle Scholar
  24. 24.
    Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA et al (2004) Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 101(3):578–586CrossRefGoogle Scholar
  25. 25.
    Twelves C, Glynne-Jones R, Cassidy J, Schüller J, Goggin T, Roos B et al (1999) Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 5(7):1696–1702PubMedGoogle Scholar
  26. 26.
    Superfin D, Iannucci AA, Davies AM (2007) Commentary: oncologic drugs in patients with organ dysfunction: a summary. Oncologist 12(9):1070–1083CrossRefGoogle Scholar
  27. 27.
    Lee JJ, Han JY, Lee DH, Kim HY, Chun JH, Lee HG et al (2006) A phase II trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer. Jpn J Clin Oncol 36(12):761–767CrossRefGoogle Scholar
  28. 28.
    Han JY, Lee DH, Kim HY, Hong EK, Yoon SM, Chun JH et al (2003) A phase II study of weekly docetaxel plus capecitabine for patients with advanced non-small cell lung carcinoma. Cancer 98(9):1918–1924CrossRefGoogle Scholar
  29. 29.
    Kumaran V, Gulati S, Paul B, Pande K, Sahni P, Chattopadhyay K (2002) The role of dual-phase helical CT in assessing resectability of carcinoma of the gallbladder. Eur Radiol 12(8):1993–1999CrossRefGoogle Scholar
  30. 30.
    Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E et al (2005) Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23(10):2332–2338CrossRefGoogle Scholar
  31. 31.
    Cho JY, Paik YH, Chang YS, Lee SJ, Lee DK, Song SY et al (2005) Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer 104(12):2753–2758CrossRefGoogle Scholar
  32. 32.
    Chowdhury Q, Reza S, Hai M, Shahid S. Capecitabine therapy in advanced gall bladder cancer: A phase II study. J Clin Oncol (Meeting Abstracts) June 2006 vol. 24 no. 18 suppl 14153Google Scholar
  33. 33.
    Iqbal S, Rankin C, Lenz HJ, Gold PJ, Ahmad SA, El-Khoueiry AB et al (2011) A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: southwest oncology group study S0202. Cancer Chemother Pharmacol 68(6):1595–1602. CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Joerger M, Huitema AD, Koeberle D, Rosing H, Beijnen JH, Hitz F et al (2014) Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. Cancer Chemother Pharmacol 73(1):113–124CrossRefGoogle Scholar
  35. 35.
    Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M et al (2002) Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 20(7):1759–1766CrossRefGoogle Scholar
  36. 36.
    Covey AM, Brown KT (2006) Palliative percutaneous drainage in malignant biliary obstruction. Part 1: indications and preprocedure evaluation. J Support Oncol 4(6):269–273PubMedGoogle Scholar
  37. 37.
    van Delden OM, Laméris JS (2008) Percutaneous drainage and stenting for palliation of malignant bile duct obstruction. Eur Radiol 18(3):448–456CrossRefGoogle Scholar
  38. 38.
    Robson PC, Heffernan N, Gonen M, Thornton R, Brody LA, Holmes R et al (2010) Prospective study of outcomes after percutaneous biliary drainage for malignant biliary obstruction. Ann Surg Oncol 17(9):2303–2311CrossRefGoogle Scholar
  39. 39.
    Tapping CR, Byass OR, Cast JE (2011) Percutaneous transhepatic biliary drainage (PTBD) with or without stenting-complications, re-stent rate and a new risk stratification score. Eur Radiol 21(9):1948–1955CrossRefGoogle Scholar
  40. 40.
    Roth LJ, Pugh EJ (1999) The role of endoscopic biliary stents in palliative care. Palliat Med 13(1):63–68CrossRefGoogle Scholar
  41. 41.
    De Palma GD, Masone S, Rega M, Simeoli I, Salvatori F, Siciliano S et al (2007) Endoscopic approach to malignant strictures at the hepatic hilum. World J Gastroenterol 13(30):4042–4045CrossRefGoogle Scholar
  42. 42.
    Freeman ML, Overby C (2003) Selective MRCP and CT-targeted drainage of malignant hilar biliary obstruction with self-expanding metallic stents. Gastrointest Endosc 58(1):41–49CrossRefGoogle Scholar
  43. 43.
    Indar AA, Lobo DN, Gilliam AD, Gregson R, Davidson I, Whittaker S et al (2003) Percutaneous biliary metal wall stenting in malignant obstructive jaundice. Eur J Gastroenterol Hepatol 15(8):915–919CrossRefGoogle Scholar
  44. 44.
    Born P, Rösch T, Triptrap A, Frimberger E, Allescher HD, Ott R et al (1998) Long-term results of percutaneous transhepatic biliary drainage for benign and malignant bile duct strictures. Scand J Gastroenterol 33(5):544–549CrossRefGoogle Scholar

Copyright information

© Indian Association of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Department of General SurgeryKing George’s Medical UniversityLucknowIndia
  2. 2.Department of RadiodiagnosisKing George’s Medical UniversityLucknowIndia
  3. 3.Department of RadiotherapyKing George’s Medical UniversityLucknowIndia

Personalised recommendations